Discover a recent study from 12 hospitals across China that has shed new light on personalised care for plaque psoriasis.

When compared with placebo, vunakizumab is a safe and efficacious treatment for moderate to severe plaque psoriasis among adults.

And beyond the physical symptoms, plaque psoriasis also frequently has negative effects on mental health and alters the lifestyle of those living with it. Here are five ways that this skin condition ...

Most extensive LEO Pharma program to date at the European Academy of Dermatology and Venereology (EADV) congress featured an ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

Psoriasis is a chronic autoimmune skin condition that causes patches of thick, red, scaly skin. Usually, the elbows, knees, ...

particularly when the disease takes a severe, chronic course. The typical skin change (primary lesion) of psoriasis is a sharply demarcated erythrosquamous plaque; it appears infiltrated and ...

NCT04785326), which compared the biosimilar to Stelara in patients with moderate to severe chronic plaque psoriasis. Findings showed the products were similar in pharmacokinetics, safety ...

It is approved for use in rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and adults with chronic moderate-to-severe plaque psoriasis. In clinical ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...